CapsoVision (CV)


Market Price (11/16/2026): $6.06 | Market Cap: $324.9 MilSector: Health Care | Industry: Life Sciences Tools & Services

CapsoVision (CV)


Market Price (11/16/2026): $6.06
Market Cap: $324.9 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -110%, 3Y Excs Rtn is -157%

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.33

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -30 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -212%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -210%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -210%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15%

Key risks
CV key risks include [1] significant financial strain and a heightened bankruptcy risk, Show more.

0 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Remote Patient Monitoring, Show more.
1 Weak multi-year price returns
2Y Excs Rtn is -110%, 3Y Excs Rtn is -157%
2 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.33
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -30 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -212%
4 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%
5 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -210%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -210%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15%
7 Key risks
CV key risks include [1] significant financial strain and a heightened bankruptcy risk, Show more.

CV in ETFs

Weight = CV's share of each fund

VTI0.00%
IWM0.01%
IWO0.02%
VTWO0.01%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 5: down 9.5% in one day (S&P 500 down 4.4%)
The decline came without company news as the market broadly fell, with the S&P 500 dropping significantly amid Wall Street's growing concerns about AI and a "sea of red" across markets.

Up 26.5% from its Jul 7 low to Aug 3, down 15.9% since (S&P 500 up 1.3%)
The stock gained on the theme of artificial intelligence, driven by the company's international launch of AI Highlights. This included a significant rise on August 3, 2026, when the company announced the launch.

Nov 13: down 3.8% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock declined after CapsoVision reported its third quarter 2026 financial results. The company posted weak revenue growth of 1% year-over-year to $4 million, and continued net losses of $7 million.

Show more
Prices as of 11/13/2026

Nov 5: down 9.5% in one day (S&P 500 down 4.4%)
The decline came without company news as the market broadly fell, with the S&P 500 dropping significantly amid Wall Street's growing concerns about AI and a "sea of red" across markets.

Up 26.5% from its Jul 7 low to Aug 3, down 15.9% since (S&P 500 up 1.3%)
The stock gained on the theme of artificial intelligence, driven by the company's international launch of AI Highlights. This included a significant rise on August 3, 2026, when the company announced the launch.

Nov 13: down 3.8% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock declined after CapsoVision reported its third quarter 2026 financial results. The company posted weak revenue growth of 1% year-over-year to $4 million, and continued net losses of $7 million.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -8.4% change in CV stock from 7/31/2026 to 11/15/2026 was primarily driven by a -6.2% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611152026Change
Stock Price ($)6.586.03-8.4%
Change Contribution By: 
Total Revenues ($ Mil)14142.6%
P/S Multiple23.021.9-4.9%
Shares Outstanding (Mil)4751-6.2%
Cumulative Contribution-8.4%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/15/2026
ReturnCorrelation
CV-8.4% 
Market (SPY)1.2%35.2%
Sector (XLV)16.6%1.8%

Fundamental Drivers

The -14.8% change in CV stock from 4/30/2026 to 11/15/2026 was primarily driven by a -10.5% change in the company's P/S Multiple.
(LTM values as of)430202611152026Change
Stock Price ($)7.086.03-14.8%
Change Contribution By: 
Total Revenues ($ Mil)14142.7%
P/S Multiple24.521.9-10.5%
Shares Outstanding (Mil)4751-7.3%
Cumulative Contribution-14.8%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/15/2026
ReturnCorrelation
CV-14.8% 
Market (SPY)5.5%22.6%
Sector (XLV)30.4%6.0%

Fundamental Drivers

The 23.6% change in CV stock from 10/31/2025 to 11/15/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511152026Change
Stock Price ($)4.886.0323.6%
Change Contribution By: 
Total Revenues ($ Mil)�140.0%
P/S Multiple�21.90.0%
Shares Outstanding (Mil)4151-19.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/15/2026
ReturnCorrelation
CV23.6% 
Market (SPY)11.8%13.2%
Sector (XLV)33.1%15.0%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/15/2026
ReturnCorrelation
CV-82.9% 
Market (SPY)87.0%11.8%
Sector (XLV)59.4%10.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
CV Return0%0%0%0%-70%-44%-83%
Peers Return4%-15%-8%-24%55%-12%-14%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
CV Win Rate0%0%0%0%33%45% 
Peers Win Rate56%53%47%42%56%55% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
CV Max Drawdown0%0%0%0%-90%-57% 
Peers Max Drawdown-33%-44%-52%-42%-36%-45% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, COCH, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

EventCVS&P 500
2010 Eurozone Sovereign Debt Crisis / Flash Crash
  % Loss-12.6%-15.4%
  % Gain to Breakeven14.4%18.2%
  Time to Breakeven190 days125 days
2008-2009 Global Financial Crisis
  % Loss-47.4%-53.4%
  % Gain to Breakeven90.2%114.4%
  Time to Breakeven922 days1085 days
Summer 2007 Credit Crunch
  % Loss-18.7%-8.6%
  % Gain to Breakeven23.0%9.5%
  Time to Breakeven1375 days47 days

Compare to A, ATEC, CERS, COCH, FRNM

In The Past

CapsoVision's stock fell -0.7% during the 2011 US Debt Ceiling Crisis & European Contagion. Such a loss loss requires a 0.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventCVS&P 500
2008-2009 Global Financial Crisis
  % Loss-47.4%-53.4%
  % Gain to Breakeven90.2%114.4%
  Time to Breakeven922 days1085 days

Compare to A, ATEC, CERS, COCH, FRNM

In The Past

CapsoVision's stock fell -0.7% during the 2011 US Debt Ceiling Crisis & European Contagion. Such a loss loss requires a 0.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About CapsoVision (CV)

CapsoVision (CV) is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) solutions for diagnosing abnormalities of the gastrointestinal (GI) tract. Its flagship product is the CapsoCam Plus, a single-use, wire-free capsule endoscopy system designed for panoramic visualization of the small-bowel mucosa. This system, which includes the physical capsule and proprietary CapsoCloud/CapsoView software, allows healthcare providers to identify conditions such as obscure GI bleeding and Crohn's disease without the need for patient-worn data recorders, offering clinicians a flexible, zero-capex workflow. CapsoVision primarily serves gastroenterologists in clinics and hospitals, selling directly in the U.S. and both directly and through qualified distributors in international markets like France, Germany, and Canada.

The company has demonstrated consistent growth, with revenues increasing from $9.8 million in 2023 to $11.8 million in 2024, representing 21% year-over-year growth, primarily driven by increasing CapsoCam Plus unit sales. CapsoVision is expanding its technology with the upcoming integration of AI-assisted reading for CapsoCam Plus, targeting FDA clearance and commercialization by late 2025 to reduce review time for clinicians. Looking ahead, the company is developing CapsoCam Colon, a pipeline product that incorporates AI for automatic polyp detection and a 3D sensor for size measurement, with revenues for its second generation targeted for the U.S. in late 2026 and the EU in early 2027. Longer-term, CapsoVision plans to adapt its panoramic imaging for new GI indications such as esophageal varices and pancreatic cancer, with feasibility studies beginning in 2025 and 2026.

AI Analysis | Feedback

  • It's like a high-tech, disposable GoPro for your digestive system, with AI to help doctors quickly find problems.
  • Think of it as the 'Cologuard of visual GI diagnostics,' offering a less invasive way for doctors to inspect your insides with a smart camera pill, instead of traditional procedures.

AI Analysis | Feedback

  • CapsoCam Plus System: A capsule endoscopy solution, including a single-use capsule and viewing software (CapsoCloud/CapsoView), designed for panoramic visualization and diagnosis of small-bowel abnormalities.
  • CapsoCam Plus with AI Assisted Reading: An upcoming update to the CapsoCam Plus system that will incorporate AI to detect and highlight suspected abnormalities, aiming to reduce clinician review time.
  • CapsoCam Colon (Pipeline): A developing capsule endoscope product designed to automatically detect polyps and measure their size in the colon using integrated AI and a 3D sensor.
  • Future CapsoCam Applications (Pipeline): Longer-term adaptations of the CapsoCam platform being explored for new GI medical indications such as esophageal conditions and pancreatic cancer.

AI Analysis | Feedback

CapsoVision (CV) sells primarily to other companies and medical institutions. Based on the provided information, the company's major customers fall into the following categories:

  • Hospitals
  • Clinics (specifically those where gastroenterologists practice)
  • Qualified exclusive distributors (for international sales)

The provided text does not name specific customer companies or their symbols.

AI Analysis | Feedback

null

AI Analysis | Feedback

Kang-Huai (Johnny) Wang, President, Chief Executive Officer and Director

Mr. Wang is a co-founder of CapsoVision, and has served as President and Chief Executive Officer since November 2024. He previously served as CapsoVision's President and Chief Technology Officer from October 2006 to October 2024. Prior to joining CapsoVision, he was Vice President of Engineering for ESS Technology and also served as Chief Executive Officer and co-founder of Divio, Inc., a video processing chip design company. Mr. Wang was also a Design Manager for C-Cube Microsystem and held various engineering roles in the semiconductor industry.

David Michael Garcia, Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer

Mr. Garcia serves as Senior Vice President, Finance at CapsoVision, overseeing the company's financial strategy, planning, and operations, and brings over 20 years of financial leadership experience. Before joining CapsoVision, he was Vice President of Financial Planning and Analysis at Matterport, Inc. from 2020 to 2025, where he played a key role in the company's initial public offering and its subsequent acquisition. His prior experience includes senior finance roles at View, Inc., IntelePeer Cloud Communications, and Align Technology, as well as earlier experience with Oracle and Deloitte.

Douglas Atkinson, Senior Vice President of Global Sales

Mr. Atkinson joined CapsoVision as Head of Global Sales in October 2016. Before CapsoVision, he was Director of Sales for MedTech Micro-Fixation from May 2015 to October 2016. He also served as Regional Sales Director at Medtronic PLC from January 2005 to April 2015, and as Regional Director of Sales and National Accounts at Stryker Corporation from May 1995 to December 2004, where he was recognized for multiple sales leadership and revenue growth awards.

AI Analysis | Feedback

Key Risks to CapsoVision (CV)

  1. Going Concern and Liquidity Risk: CapsoVision has a history of operating losses, an accumulated deficit, and a stated substantial doubt about its ability to continue as a going concern, which could adversely impact its ability to fund growth strategies and meet cash and liquidity needs.
  2. Regulatory Clearance Delays or Failure: The company's ability to commercialize its updated CapsoCam Plus with AI-assisted reading technology and its new pipeline product, CapsoCam Colon, is dependent on receiving timely FDA 510(k) clearances and EU CE Marks, which may be delayed or not obtained at all, impacting future revenue generation.
  3. Dependence on a Single Product and Market Competition: All current revenues are derived from the CapsoCam Plus for small bowel visualization, making the company highly dependent on the continued success and growth of this single product. Its ability to grow is also subject to intense competition from existing FDA-cleared products and established market players.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

CapsoVision (CV) anticipates several key drivers for future revenue growth over the next 2-3 years:

  1. Expanded Sales of CapsoCam Plus System: The company plans to further grow its existing sales and marketing team to increase sales of its CapsoCam Plus small-bowel capsule system, building on its consistent revenue growth and high customer retention rate of approximately 90% in 2024. This includes strengthening its market presence, as evidenced by establishing a direct sales team in Germany in 2023.
  2. Commercialization of AI-Assisted CapsoCam Plus: CapsoVision is updating its CapsoCam Plus with self-developed AI-assisted reading technology. The company targets FDA 510(k) and EU submissions in the second half of 2025, with clearance of the updated capsule and subsequent commercialization by the end of 2025. This enhancement is expected to make capsule endoscopy more financially attractive to practices by reducing video review time.
  3. Launch of CapsoCam Colon System: To expand beyond small-bowel sales, CapsoVision is developing CapsoCam Colon, a new capsule endoscope for colon visualization, incorporating AI for polyp detection and a 3D sensor for polyp-size measurement. The company targets U.S. revenues for its second-generation CapsoCam Colon system beginning in the second half of 2026, following FDA 510(k) clearance, and EU revenues in early 2027, after receiving a CE Mark.

AI Analysis | Feedback

null

Peer Outperformance in Life Sciences Tools & Services

CV has trailed 58% of its 108 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that CV has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
63%
of 124 industry peers · 17.8% return
3Y
21%
of 113 industry peers · -82.9% return
5Y
42%
of 108 industry peers · -82.9% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten CV by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is CV's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 10.3%56.1%108.0% CAH 517% · MCK 409% · COR 206%
Health Care Services 20 30.9%20.9%12.5% RDNT 145% · HIMS 141% · DGX 95%
Managed Health Care 8 72.3%-2.6%2.7% OSCR 155% · HQY 54% · HUM 8%
Health Care Facilities 26 18.0%25.0%-6.7% THC 257% · NHC 227% · EHC 196%
Health Care Equipment 50 7.8%11.1%-15.2% GKOS 401% · UFPT 346% · TMDX 255%
Pharmaceuticals 60 -15.0%7.7%-39.5% LQDA 1081% · KNSA 639% · XERS 572%
Health Care Supplies 11 26.2%6.1%-39.8% LNTH 241% · HAE 112% · MMSI 27%
Life Sciences Tools & Services ← 109 -15.3%-17.9%-74.4% AXGN 378% · MEDP 199% · NTRA 175%
Biotechnology 365 -26.3%-32.0%-81.4% ELVN 1259% · TRVI 1141% · DNTH 1129%
Health Care Technology 22 -20.8%-57.2%-82.3% VEEV -4% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

CVAATECCERSCOCHFRNMMedian
NameCapsoVis.Agilent .Alphatec Cerus Envoy Me.Freenome  
Mkt Price6.06173.987.081.996.7410.416.91
Mkt Cap0.349.11.10.4--0.8
Rev LTM147,3728402270-227
Op Inc LTM-301,639-26-2-24--24
FCF LTM-291,267-100-22--10
FCF 3Y Avg-1,257-71-3-22--13
CFO LTM-291,609613-22-3
CFO 3Y Avg-1,6305-1-21-2

Growth & Margins

CVAATECCERSCOCHFRNMMedian
NameCapsoVis.Agilent .Alphatec Cerus Envoy Me.Freenome  
Rev Chg LTM6.4%8.6%15.3%13.7%11.1%-11.1%
Rev Chg 3Y Avg-2.0%23.2%13.8%0.4%-7.9%
Rev Chg Q0.8%8.1%12.6%9.5%57.1%-9.5%
QoQ Delta Rev Chg LTM0.2%1.9%3.0%2.3%11.6%-2.3%
Op Inc Chg LTM-30.1%13.5%65.3%74.0%-19.5%-13.5%
Op Inc Chg 3Y Avg-5.3%38.1%54.0%-20.1%-21.7%
Op Mgn LTM-212.1%22.2%-3.0%-1.1%-10,343.3%--3.0%
Op Mgn 3Y Avg-22.1%-12.4%-4.2%-9,221.1%--8.3%
QoQ Delta Op Mgn LTM5.0%0.7%1.7%-0.4%1,067.8%-1.7%
CFO/Rev LTM-209.7%21.8%7.3%1.5%-9,624.2%-1.5%
CFO/Rev 3Y Avg-23.8%-0.6%-0.5%-8,907.8%--0.6%
FCF/Rev LTM-210.3%17.2%-1.2%0.2%-9,710.4%--1.2%
FCF/Rev 3Y Avg-18.3%-12.1%-1.9%-9,121.7%--7.0%

Valuation

CVAATECCERSCOCHFRNMMedian
NameCapsoVis.Agilent .Alphatec Cerus Envoy Me.Freenome  
Mkt Cap0.349.11.10.4--0.8
P/S22.06.71.31.8--4.2
P/Op Inc-10.429.9-43.6-162.9---27.0
P/EBIT-10.427.8-26.2-1,704.7---18.3
P/E-10.534.1-12.8-55.0---11.7
P/CFO-10.530.518.2115.0--24.3
Total Yield-9.6%3.5%-7.8%-1.8%---4.8%
Dividend Yield0.0%0.6%0.0%0.0%--0.0%
FCF Yield 3Y Avg-3.0%-8.5%-1.0%---1.0%
D/E0.00.10.50.2--0.1
Net D/E-0.10.00.50.0--0.0

Returns

CVAATECCERSCOCHFRNMMedian
NameCapsoVis.Agilent .Alphatec Cerus Envoy Me.Freenome  
1M Rtn-7.2%0.6%-32.3%-8.7%3.6%-11.4%-8.0%
3M Rtn-6.2%17.3%-27.7%-33.2%3.6%-9.9%-8.0%
6M Rtn-6.1%56.3%-7.6%-15.0%3.6%-19.9%-6.8%
12M Rtn18.4%19.4%-64.1%22.8%3.6%-19.9%11.0%
3Y Rtn-82.8%55.8%-37.8%15.0%3.6%-19.9%-8.2%
1M Excs Rtn-4.4%0.7%-33.6%-10.3%5.2%-13.6%-7.4%
3M Excs Rtn-4.3%19.0%-23.5%-31.4%5.2%-18.3%-11.3%
6M Excs Rtn-9.0%53.4%-10.4%-17.8%0.8%-22.8%-9.7%
12M Excs Rtn-1.9%4.5%-77.1%9.4%-7.6%-31.2%-4.7%
3Y Excs Rtn-157.0%-11.2%-107.0%-54.9%-70.2%-93.8%-82.0%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024
Products (capsules and capsule reading devices)1311
Services (cloud-based video delivery and reading services)11
Total1412


Price Behavior

Price Behavior
Market Price$6.03 
Market Cap ($ Bil)0.3 
First Trading Date12/29/2006 
Distance from 52W High-58.2% 
   50 Days200 Days
DMA Price$6.53$6.38
DMA Trendupdown
Distance from DMA-7.6%-5.5%
 3M1YR
Volatility51.8%98.0%
Downside Capture136.99105.96
Upside Capture134.65107.30
Correlation (S&P 500)35.8%12.8%
CV Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.390.240.910.700.790.15
Up Beta1.53-2.26-0.57-1.19-0.350.10
Down Beta1.451.060.211.450.740.27
Up Capture38%90%156%78%151%-5%
Bmk +ve Days12182862130427
Stock +ve Days11253262122167
Down Capture-50%-45%133%116%99%35%
Bmk -ve Days10253664121325
Stock -ve Days10173163125164

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CV
CV8.9%98.0%0.51-
Sector ETF (XLV)25.8%16.8%1.1813.7%
Equity (SPY)11.6%13.7%0.5412.4%
Gold (GLD)-7.9%28.9%-0.290.7%
Commodities (DBC)33.8%21.3%1.26-5.8%
Real Estate (VNQ)10.7%14.2%0.475.7%
Bitcoin (BTCUSD)-33.0%43.7%-0.792.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CV
CV7.6%89.8%0.68-
Sector ETF (XLV)9.1%15.4%0.3911.6%
Equity (SPY)11.5%17.3%0.4913.0%
Gold (GLD)15.9%19.2%0.661.1%
Commodities (DBC)7.8%19.6%0.28-2.3%
Real Estate (VNQ)1.3%18.9%-0.046.1%
Bitcoin (BTCUSD)2.2%51.6%0.233.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CV
CV3.7%89.8%0.68-
Sector ETF (XLV)13.0%16.8%0.6411.6%
Equity (SPY)15.5%18.0%0.7313.0%
Gold (GLD)11.1%16.6%0.541.1%
Commodities (DBC)7.6%18.1%0.33-2.3%
Real Estate (VNQ)6.3%20.7%0.266.1%
Bitcoin (BTCUSD)58.4%66.2%0.983.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity2.0 Mil
Short Interest: % Change Since 10152026-10.6%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest14.3 days
Basic Shares Quantity50.6 Mil
Short % of Basic Shares3.9%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-3.8%  
8/13/2026-4.9%-13.0%-4.1%
5/14/2026-11.6%-7.3%-1.0%
3/26/2026-0.3%-1.2%-15.4%
11/13/2025-9.7%-6.0%111.6%
8/14/2025-4.2%-1.0%7.7%
SUMMARY STATS   
# Positive002
# Negative653
Median Positive  59.7%
Median Negative-4.5%-6.0%-4.1%
Max Positive  111.6%
Max Negative-11.6%-13.0%-15.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2026-3.8%  
8/13/2026-4.9%-13.0%-4.1%
5/14/2026-11.6%-7.3%-1.0%
3/26/2026-0.3%-1.2%-15.4%
11/13/2025-9.7%-6.0%111.6%
8/14/2025-4.2%-1.0%7.7%
SUMMARY STATS   
# Positive002
# Negative653
Median Positive  59.7%
Median Negative-4.5%-6.0%-4.1%
Max Positive  111.6%
Max Negative-11.6%-13.0%-15.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/13/202610-Q
03/31/202605/14/202610-Q
12/31/202503/26/202610-K
09/30/202511/13/202510-Q
06/30/202508/14/202510-Q
03/31/202507/03/2025424B4
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/13/202610-Q
03/31/202605/14/202610-Q
12/31/202503/26/202610-K
09/30/202511/13/202510-Q
06/30/202508/14/202510-Q
03/31/202507/03/2025424B4

Insider Activity

Updated 9/23/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Harari, Eliyahou ET AL trust.Buy92320265.691,757,4699,999,9997,946,051Form
2Shen, Ching Hang Star One Global Capital LimitedBuy91820265.69878,7344,999,99616,652,667Form
3Harari, Eliyahou ET AL trust.Buy72020266.7361,068410,98822,499,191Form
4Harari, Eliyahou ET AL trust.Buy71020266.0981,300495,11719,987,691Form
5Harari, Eliyahou ET AL trust.Buy70220267.3513,850101,81123,528,721Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Harari, Eliyahou ET AL trust.Buy92320265.691,757,4699,999,9997,946,051Form
2Shen, Ching Hang Star One Global Capital LimitedBuy91820265.69878,7344,999,99616,652,667Form
3Harari, Eliyahou ET AL trust.Buy72020266.7361,068410,98822,499,191Form
4Harari, Eliyahou ET AL trust.Buy71020266.0981,300495,11719,987,691Form
5Harari, Eliyahou ET AL trust.Buy70220267.3513,850101,81123,528,721Form
Core Cache Last Updated: 11/15/2026